Company Roivant Sciences Ltd.

ROIV

BMG762791017

Pharmaceuticals

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Holdings

Company contact information

Sector

Ratings for Roivant Sciences Ltd.

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:06 2024-04-23 pm EDT			5-day change	1st Jan Change
10.94 ^USD	+3.16%		+2.10%	-2.63%

Apr. 05	Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit	MT
Apr. 04	Moderna Suffers Setback in Lawsuit by Arbutus	MT

Roivant Sciences Ltd. is a commercial-stage biopharmaceutical company that seeks to improve the lives of patients by accelerating the development and commercialization of medicines that matter. The Companyâs pipeline is focused on inflammation and immunology and includes VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; batoclimab and IMVT-1402, fully human monoclonal antibodies targeting the neonatal Fc receptor (FcRn) in development across several IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody in development for ulcerative colitis and Crohnâs disease, in addition to various other therapies in various stages of clinical development. The Company advances its pipeline by creating nimble subsidiaries or Vants to develop and commercialize its medicines and technologies. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business.

Number of employees: 904

Managers	Title	Age	Since
Matthew Gline CEO	Chief Executive Officer	40	16-02-29
Richard Pulik DFI	Director of Finance/CFO	-	21-09-27
Eric Venker PSD	President	37	13-12-31
Mayukh Sukhatme PSD	President	48	14-12-31
Drew Kramer CTO	Chief Tech/Sci/R&D Officer	-	-
Amy Mahery PRN	Corporate Officer/Principal	-	22-07-31
Kelly Graff HRO	Human Resources Officer	-	19-12-31
Jo Chen LAW	General Counsel	-	20-02-29
Srini Ramanathan PRN	Corporate Officer/Principal	-	22-05-01
Navneet Alag PRN	Corporate Officer/Principal	-	22-01-31

Members of the board	Title	Age	Since
Meghan Fitzgerald BRD	Director/Board Member	53	23-03-12
Keith Manchester BRD	Director/Board Member	55	13-12-31
Dan Gold BRD	Director/Board Member	56	19-12-31
Melissa Epperly BRD	Director/Board Member	46	22-06-28
Mayukh Sukhatme PSD	President	48	14-12-31
Ilan Oren CHM	Chairman	40	13-12-31
Jim Momtazee BRD	Director/Board Member	-	21-09-30
Matthew Gline CEO	Chief Executive Officer	40	16-02-29

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	805,846,006	626,986,939 ( 77.80 %)	0	77.80 %

Name	Equities	%	Valuation
QVT Financial LP 13.97 %	112,541,536	13.97 %	1 186 M $
Dexcel Ltd. 12.76 %	102,849,443	12.76 %	1 084 M $
SB Investment Advisers (UK) Ltd. 9.063 %	73,031,667	9.063 %	770 M $
Viking Global Investors LP 8.608 %	69,368,961	8.608 %	731 M $
QVT Financial LP 8.279 %	66,719,779	8.279 %	703 M $
Vivek Ramaswamy 6.630 %	53,431,426	6.630 %	563 M $
Fidelity Management & Research Co. LLC 4.589 %	36,976,248	4.589 %	390 M $
Morgan Stanley Investment Management, Inc. 2.721 %	21,927,044	2.721 %	231 M $
BlackRock Advisors LLC 2.459 %	19,817,025	2.459 %	209 M $
Rubric Capital Management LP 2.358 %	19,000,000	2.358 %	200 M $

Name	Equities	%	Valuation
IMMUNOVANT, INC. 54.93%	79,805,331	54.93%	2,578,510,245 $
ARBUTUS BIOPHARMA CORPORATION 21.64%	38,847,462	21.64%	100,226,452 $

Roivant Sciences Ltd.

50 Broadway 7th Floor

SW1H 0BD, London

+44 20 7400 3347

http://www.roivant.com

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

10.6 USD

Average target price

16.08 USD

Spread / Average Target

+51.70%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Pharmaceuticals

Pharmaceuticals

Other Pharmaceuticals

	1st Jan change	Capi.
ROIVANT SCIENCES LTD.	-2.63%	8.54B
ELI LILLY AND COMPANY	+27.92%	659B
NOVO NORDISK A/S	+27.68%	557B
JOHNSON & JOHNSON	-4.59%	359B
MERCK & CO., INC.	+16.38%	322B
ABBVIE INC.	+9.39%	297B
ASTRAZENECA PLC	+6.30%	215B
NOVARTIS AG	+4.80%	210B
ROCHE HOLDING AG	-6.05%	200B
PFIZER, INC.	-8.58%	149B

Other Pharmaceuticals